Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price target of $18.00. The company’s shares closed yesterday at $2.98.
According to TipRanks, Goldstein is a 2-star analyst with an average return of 0.0% and a 34.88% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Adaptimmune Therapeutics.
Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $13.67.
See the top stocks recommended by analysts >>
AUTL market cap is currently $270.9M and has a P/E ratio of -1.66.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL:
